4 recruiting, 4 unknown, 3 completed, 2 active not recruiting. 15 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Recruiting 4, Unknown 4, Completed 3, Active not recruiting 2, Withdrawn 2 |
| Phase 1 | 1 | Completed 1 |
Follow Undifferentiated Pleomorphic Sarcoma: new trials by email Literature Review of Undifferentiated Pleomorphic Sarcoma trials Research Report on Undifferentiated Pleomorphic Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Association of pembrolizumab + cabozantinib - Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma | Phase 2 | Recruiting | Institut Bergonié | 119 | 2022-04-25 | 2025-10-07 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Propranolol, Pembrolizumab - Soft Tissue Sarcoma Adult, Angiosarcoma | Phase 2 | Recruiting | Niels Junker | 80 | 2021-08-17 | 2023-07-27 |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Envafolimab, Ipilimumab - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 207 | 2020-12-09 | 2024-05-17 |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin - Sarcoma, Myxofibrosarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-04-01 | 2026-04-23 |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging - Leiomyosarcoma, Liposarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2019-12-31 | 2026-11-12 |
| Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Anlotinib, Toripalimab, Blood Draw - Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Unknown | Di Wu | 25 | 2019-07-19 | 2019-07-10 |
| A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Eribulin, Pembrolizumab - Sarcoma, Liposarcoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 57 | 2019-06-04 | 2025-08-28 |
| Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Hypofractionated radiotherapy, Hyperthermia - Sarcoma, Alveolar Soft Part Sarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 30 | 2018-06-01 | 2021-02-01 |
| CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 1 / Phase 2 | Completed | BioAtla, Inc. | 245 | 2018-02-15 | 2025-09-23 |
| Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery Ipilimumab, Nivolumab, Radiation Therapy - Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2017-10-04 | 2026-09-14 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy - Sarcoma, Fibrosarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 46 | 2017-02-11 | 2021-01-22 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Dexrazoxane, Doxorubicin - Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 73 | 2016-02-22 | 2023-11-07 |
Histiocytoma, Malignant Fibrous (15) · Sarcoma (13) · Liposarcoma (9) · Leiomyosarcoma (8) · Dermatofibrosarcoma (7) · Sarcoma, Synovial (6) · Hemangiosarcoma (5) · Fibrosarcoma (4) · Neurofibrosarcoma (4) · Bone Neoplasms (2) · Liposarcoma, Myxoid (2) · Osteosarcoma (2) · Rhabdomyosarcoma (2) · Sarcoma, Alveolar Soft Part (2) · Desmoplastic Small Round Cell Tumor (1)
Histiocytoma (15) · Neoplasms by Histologic Type (15) · Neoplasms, Connective Tissue (15) · Neoplasms, Connective and Soft Tissue (15) · Neoplasms, Fibrous Tissue (15) · Neoplasms (14) · Neoplasms, Adipose Tissue (9) · Neoplasms, Muscle Tissue (9) · Fibrosarcoma (5) · Neoplasms, Vascular Tissue (5) · Neoplasms, Nerve Tissue (4) · Nerve Sheath Neoplasms (4) · Nervous System Diseases (4) · Nervous System Neoplasms (4) · Neurofibroma (4)
pembrolizumab (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Docetaxel (2) · Doxorubicin (2) · Gemcitabine (2) · Ipilimumab (2) · Radiation (2) · Radiation Dose Hypofractionation (2) · Radiotherapy (2) · Biopsy (1) · Biopsy, Needle (1) · Blood Specimen Collection (1) · CTLA-4 Antigen (1) · Dactinomycin (1) · Dexrazoxane (1)
Brown University (2) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · BioAtla, Inc. (1) · Dana-Farber Cancer Institute (1) · Di Wu (1) · HRYZ Biotech Co. (1) · Institut Bergonié (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Niels Junker (1) · Tracon Pharmaceuticals Inc. (1) · Washington University School of Medicine (1)
United States (9) · China (2) · Poland (2) · Canada (1) · Denmark (1) · France (1) · Hong Kong (1) · Norway (1) · Sweden (1) · Taiwan (1) · United Kingdom (1)
Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Charles Theuer, MD, PhD (1) · Christina L Roland (1) · Don S Dizon, MD (1) · Edmund Bartlett, MD (1) · Galina G Lagos, MD (1) · Niels Junker, MD, PhD (1) · Steven I Robinson (1) · Suzanne George, MD (1) · Xing Zhang (1) · Zhang Xing (1)
PMID 30249211, PMID 34722269, PMID 35115306, PMID 38236580, PMID 38579194, PMID 42194972
UM1CA186686 (1), UM1CA186709 (1)